Dublin, March 29, 2018 -- The "Global Ocular Drug Delivery Technology Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to ResearchAndMarkets.com's offering.
The global ocular drug delivery technology market was valued at US$ 15,500 Mn in 2016, and is expected to reach US$ 25,697 Mn by 2025, expanding at a CAGR of 5.81% from 2017 to 2025.
Market Insights
Ocular drug delivery technology market is growing owing to rising prevalence of eye disorders. The complex of eye anatomy makes the treatment to be very challenging, hence innovations in ophthalmic treatment is still emerging with potential benefits. Presently available therapies not proven to be sufficient to treat every possible sites of eye, therefore enhanced product formulation with improved technology became vital.
According to the statistics of World Health Organizations, 285 million people are visually impaired across the world and this global burden of eye disorder is increasing with rapidly growing ageing population. WHO has taken an initiative named VISION 2020 to abolish the possible causes of blindness and provide better eye-care infrastructure to make easily accessible eye-care.
The ocular drug delivery technology market is predicted to experience substantial growth due to growing elderly population, increasing medical interventions and increasing prevalence of eye diseases. The increasing adoption of technologically advanced products, healthcare expenditure for R&D to develop innovative products boost up the growth of the ocular drug delivery technology market.
The ocular drug delivery technology market is classified on the basis of technology type and the classifications are of below types:
- Topical
- Ophthalmic injection/Intravitreal injection
- Ocular insert
- Ocular implant
- Others
Topical treatment dominates the overall market of ocular drug delivery technology in terms of technology types.
The ocular drug delivery technology market is further segmented on the basis of indication and the sub-segments are as follows:
- Cataract
- Glaucoma
- Age related macular degeneration
- Diabetic Retinopathy
- Eye infection
- Dry eyes
- Others
Geographically, in the year 2016, North America held the major share of ocular drug delivery technology market followed by Europe. The increasing burden of visual impairment is majorly due to cataract, glaucoma or diabetes which is directly correlated with ageing population.
The increasing R&D expenditure in healthcare research to develop innovative products to obtain improved outcomes and the acceptance of the new technologies among the healthcare professionals boost up the ocular drug delivery technology market growth. The developing eye-care infrastructure, huge number of population suffering from eye disorders and increasing elderly population fuel the growth of the ocular drug delivery technology market in Asia-Pacific region and it is expected to face significant growth in upcoming years due to the growing trend of health awareness among public.
Market Competition Assessment
The ocular drug delivery technology market currently contains multiple companies having their products marketed. The manufacturers are developing new innovative products and the market is growing due to increasing adoption and accessibilities of these products.
The companies include Alimera Sciences, Valeant Pharmaceuticals International, Inc., Ocular Therapeutix, Inc., Allergan, Plc., Clearside Biomedical, EyeGate Pharma, Envisia Therapeutics, Inc., Graybug Vision Inc., and others.
Key Market Movements:
- The rising prevalence of eye disorder, growing ageing population, rising public awareness, increasing number of medical intervention, expanding eye-care set up to reduce global burden of eye diseases, increasing healthcare expenditure for R&D to manufacture newer and innovative products boost up the growth of ocular drug delivery technology market.
Key Topics Covered:
Chapter 1 Preface
1.1 Report Description
1.2 Research Scope
1.3 Research Methodology
Chapter 2 Executive Summary
2.1 Ocular Drug Delivery Technology Market Portraiture
2.2 Ocular Drug Delivery Technology Market, by Technology Type, 2016 (US$ Mn)
2.3 Ocular Drug Delivery Technology Market, by Indication Type, 2016 (US$ Mn)
2.4 Ocular Drug Delivery Technology Market, by Geography, 2016 (Value %)
Chapter 3 Global Ocular Drug Delivery Technology Market Analysis
3.1 Global Ocular Drug Delivery Technology Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Analysis: Global Ocular Drug Delivery Technology Market, 2016 (Value %)
Chapter 4 Global Ocular Drug Delivery Technology Market Analysis, By Technology Type
4.1 Overview
4.1.1 Market Attractive Proposition of Ocular Drug Delivery Technology Market, by Technology Type, 2016
4.2 Topical Medication
4.4 Ocular Insert
4.5 Ocular Implant
4.6 Others
Chapter 5 Global Ocular Drug Delivery Technology Market Analysis, By Indication Type
5.1 Overview
5.1.1 Market Attractive Proposition of Ocular Drug Delivery Technology Market, by Indication Type, 2016
5.3 Glaucoma
5.4 Age Related Macular Degeneration
Chapter 6 Global Ocular Drug Delivery Technology Market, By Geography
Chapter 7 Company Profiles
- Alimera Sciences
- Valeant Pharmaceuticals International, Inc.
- Ocular Therapeutix
- Allergan, Plc.
- Clearside Biomedical
- EyeGate Pharma
- Envisia Therapeutics, Inc.
- Graybug Vision Inc.
For more information about this report visit https://www.researchandmarkets.com/research/jlkbdb/global_ocular?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Transdermal and Transmucosal Drug Delivery, Optical Disorders Drugs


Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges
Telegram Restored on Apple App Store After Temporary Removal
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership
Jetstar to Charge for Overhead Cabin Bags From February
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 



